You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 64 No. 6, June 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Neurogenetics
 •Movement Disorders
 •Parkinson Disease/ Parkinsonian Disorders
 •Neurology, Other
 •Alert me on articles by topic

Inflammatory Cytokine Gene Polymorphisms and Increased Risk of Parkinson Disease

Angelika D. Wahner, PhD; Janet S. Sinsheimer, PhD; Jeff. M. Bronstein, MD, PhD; Beate Ritz, MD, PhD

Arch Neurol. 2007;64(6):836-840.

Background  The proinflammatory cytokines tumor necrosis factor {alpha} (TNF-{alpha}) and IL-1β (interleukin 1β) have a role in neuroinflammation, and functional polymorphisms in the TNF-{alpha} and IL-1β genes may affect susceptibility to Parkinson disease (PD).

Objective  To investigate whether functional DNA polymorphisms of the TNF-{alpha} and IL-1β genes affect the risk of PD.

Design  Population-based case-control study.

Setting  Three rural California counties (Fresno, Tulare, and Kern).

Participants  Two hundred eighty-nine incident idiopathic PD cases and 269 population control subjects, marginally matched by age, sex, and race/ethnicity.

Main Outcome Measures  Genotypes of IL-1β-511 and TNF-{alpha}-308.

Results  We observed a greater than 2-fold increased risk of PD among carriers of the homozygous variant genotype of IL-1β-511 (odds ratio [OR], 2.26; 95% confidence interval [CI], 1.27-4.02) and the homozygous variant genotype of TNF-{alpha}-308 (OR, 2.49; 95% CI, 0.90-6.85) and an almost 3-fold increased risk among carriers of the homozygous variant genotype for either or both polymorphisms (OR, 2.92; 95% CI, 1.66-5.16).

Conclusions  A smaller magnitude of PD risk increase among carriers of the heterozygous genotype for either or both polymorphisms suggests a gene-dosing effect (OR, 1.45; 95% CI, 0.97-2.16; P<.001 for trend). Results were not sensitive to exclusion of all nonwhite subjects or to adjustment for nonsteroidal anti-inflammatory drug use or smoking.


Author Affiliations: Department of Epidemiology, UCLA School of Public Health (Drs Wahner and Ritz), and Departments of Biomathematics and Human Genetics (Dr Sinsheimer) and Neurology (Dr Bronstein), David Geffen School of Medicine at UCLA, University of California, Los Angeles, and Greater Los Angeles Veterans Administration Medical Center (Dr Bronstein), Los Angeles.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.